US Market Report Suite for Diabetes Monitoring, Treatment and Drug Delivery 2017 – MedSuite

ReportIcon-Diabetes-MS

US Market Report Suite for Diabetes Monitoring, Treatment and Drug Delivery 2017 – MedSuite

  • Year: 2017
  • Scope: 2013-2023
  • Region: United States
  • Published Date: 10/1/2016
  • Pages: 273
  • Type: MedSuite

0

The full report suite on the U.S. market for diabetes monitoring, treatment and drug delivery includes blood glucose meters, blood glucose test strips, lancets and lancing devices, continuous glucose monitoring (CGM), insulin, inulin pens, insulin syringes and insulin pumps. Sanofi and Novo Nordisk recently launched next-generation insulin products: insulin glargine U-300 (Toujeo®) and insulin degludec (Tresiba®), respectively. Both of these insulin analogs are “ultra-long-acting” and have an average duration of 24 to 36 hours, which means that patients will only be required to perform once-daily injections. Novo Nordisk is currently developing Ryzodeg®, a premixed insulin analog comprising insulin degludec (Tresiba®) and insulin aspart (NovoLog®), in addition to an “ultra-rapid-acting” insulin analog, which are both expected to be launched during the forecast period. The insulin-dependent patient population is expected to transition to next-generation insulin products and will contribute to the growth of the insulin market and associated insulin delivery markets.


Diabetes mellitus is a multifaceted disease that yields various approaches in terms of diagnosis, treatment and drug delivery. Products for maintenance and treatment of diabetes can be of high volume and low cost or of relatively low volume and high cost. The U.S. diabetes monitoring, treatment and drug delivery market increased in value in 2016 and growth is expected to persist over the forecast period. Growth will be driven by the increasing prevalence of diabetes in the U.S. and technological advancements made in certain segments, particularly insulin pumps and continuous glucose monitoring (CGM). Limitations to market growth include pricing pressure due to recent CMS reimbursement changes and the negative impact on the overall blood glucose monitoring market. The recent influx of low-price competitors in the blood glucose test strip segment has also placed downward pressure on prices and resulted in market value contractions despite the growing volume and increasing number of diabetics testing their blood glucose levels.

Report Features

  • Market analyses include: unit sales, average sales price (ASPs), market value & growth trends
  • Market drivers & limiters for each chapter segment
  • Competitive analysis for each chapter segment
  • Section on recent mergers & acquisitions

Report Specifics, New Content, Major Trends & Report Changes

  • Added CPT and HCPCS codes for continuous glucose monitoring (CGM), blood glucose test strips, lancets and lancing devices
  • Added professional CGM segment
  • Added safety insulin pen needle segment
  • Takes into account CMS reimbursement changes made in July 2016 for test strips, lancets and lancing devices
The "US Market Report Suite for Diabetes Monitoring, Treatment and Drug Delivery 2017 - MedSuite" includes analysis on the following companies currently active in this market: Sanofi Novo Nordisk Eli Lilly Medtronic Johnson & Johnson Becton Dickinson Abbott Roche DexCom Ascensia Insulet Trividia Health Tandem Nova Biomedical Valeritas *Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.

Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology

Thank you!

CLOSE
Report Type Info

Single License: A single license is for use by a single individual only. Usage rights may not be transferred, sold or distributed by any means.

Site License: A site license allows sharing of the reports between various users within the purchasing company’s designated business address within this agreement.

Corporate License: A corporate license is for the use of one corporation. A corporation is defined as any business entity incorporated under a single name. Separate corporations operating under the same parent company are not included in this license.

Executive Summary: An in-depth summary of the reports associated with the related MedSuite product.

CLOSE

Login

Sign Up

or Login

×